Libido
aka sexual desire
Declining interest in sex is one of the most common symptoms of perimenopause affecting more than 50% of all women (Nappi & Lachowsky, 2009)
TLDR. If you've noticed your interest in sex shifting - feeling less present, harder to access, or just different than it used to be - you're not alone. There are actions we can take to rebuild sexual desire.
Changes in libido are among the most common symptoms of perimenopause, affecting more than 50% of women. Given the self stated importance of maintaining an active sex life, this is also something women are looking to address (Nappi & Lachowsky, 2009). They’re also among the least discussed, which means many women spend years wondering if something is wrong with them before they learn that what they’re experiencing has a name, a physiological explanation, and real options. This article is here to give you that foundation.
Understanding your desire: a different model
While spontaneous desire may have dominated our 20's, it isn't the only type of sexual desire. If you don't feel desire out of nowhere but find you're interested once you're actually engaged, that's not lack of desire, its a different kind of desire. You're experiencing responsive desire, and it's a normal, healthy pattern and type of desire, not a problem to fix.
Before diving into hormones and research, there’s a framework worth understanding first — one that changes how many women think about their own sexuality and whether anything has actually gone “wrong.”
Most of us grew up with an implicit model of sexual desire as something that arises spontaneously — a feeling that shows up on its own and leads to wanting sex. Researchers call this spontaneous desire. It’s the model underlying most sexual scripts we’ve encountered, and it tends to be more characteristic of how desire works for men and for younger women.
But research on female sexual response, most notably the work of Dr. Rosemary Basson (Basson. R, 2000), describes a different pattern that is equally healthy and far more common in women, especially in longer-term relationships: responsive desire. In this model, desire doesn’t come first. It follows arousal. A woman may have no spontaneous interest in sex, but when she engages — when the context is right, when there is touch, connection, or stimulation — desire and arousal can develop. She may end up excited to be there, even if that's not the level of enthusiasm she started with.
This distinction matters enormously during perimenopause. As hormones shift, many women whose desire was previously spontaneous find it becoming more responsive. The shift can feel like a loss when measured against a prior baseline, or against an implicit standard of what desire “should” look like. Understanding that the model itself may have changed — not disappeared — can reframe the entire conversation.
What tends to suffer most during perimenopause is not desire itself, but the conditions that activate responsive desire: uninterrupted time, physical comfort, reduced stress, and emotional connection. Many of the approaches discussed later in this article work precisely by restoring those conditions rather than directly targeting desire as an isolated variable.
Physiological Foundations
How Common Are These Changes?
Changes in sexual desire are among the most common — and least discussed — symptoms of the menopausal transition.
Despite the prevalence of reduced desire, sex continues to matter deeply. The SWAN cohort — 3,302 women across five racial and ethnic groups — found that over 75% of middle-aged women reported that sex was moderately or extremely important to them (Cain et al, 2003). That gap between how much sex matters and how often it’s disrupted is exactly the reason this topic deserves more airtime than it gets.
The Hormonal Picture
Estrogen, progesterone, and testosterone are the three primary ovarian hormones influencing female sexual function. Their interconnected decline and fluctuation during perimenopause affect desire, arousal, lubrication, and tissue integrity simultaneously.
Estradiol (E2): During perimenopause, estradiol production becomes erratic before declining. Estrogen directly supports vaginal and vulvar tissue health, genital blood flow, nerve function, and lubrication capacity. As levels fluctuate unpredictably, many women notice inconsistent arousal responsiveness and increasing vaginal discomfort. Falling estrogen also contributes to vasomotor symptoms — hot flashes and night sweats — which further compound sleep disruption and fatigue, indirect but significant drivers of reduced sexual interest.
Progesterone: Progesterone levels decline steadily during perimenopause, often before significant estrogen changes. Progesterone insufficiency contributes to mood changes, anxiety, and disrupted sleep — all of which are known correlates of decreased sexual desire.
Testosterone: Testosterone plays a central role in female sexual motivation, initiating sexual activity and modulating clitoral and vaginal physiology for lubrication, sensation, and engorgement. Unlike estrogen and progesterone, testosterone levels decline gradually and steadily with aging (Davidson et al., 2005). The Seattle Midlife Women’s Health Study (SMWHS) — a longitudinal cohort of 286 women followed across early reproductive, menopausal transition, and early postmenopausal stages at a single U.S. site — found that women with higher urinary testosterone levels reported significantly higher levels of sexual desire across the transition (Woods et al., 2010).
Sex Hormone-Binding Globulin (SHBG) and Your Contraception History
An important and often overlooked variable is SHBG, a protein that binds both estrogen and testosterone, rendering them biologically unavailable. Certain systemic estrogen preparations — particularly oral formulations — can increase SHBG production, thereby reducing free (bioavailable) testosterone and estradiol. This is a relevant clinical consideration when evaluating the relationship between hormone therapy and libido outcomes (Zimmerman, 2014).
The same hepatic mechanism applies to combined oral contraceptives, which can raise SHBG substantially and suppress free testosterone both through first-pass liver exposure and by directly suppressing ovarian androgen production. Many perimenopausal women arrive in this transition having used combined oral contraceptives for years or even decades, meaning SHBG elevation from contraceptive history may compound the age-related decline in testosterone bioavailability. A thorough libido assessment during perimenopause should therefore include current and recent contraceptive method as part of the clinical picture — and may warrant a conversation about whether the chosen method still reflects your current needs. This is explored further in the section on pharmaceutical options and COCs.
Given the varying delivery mechanism for hormonal IUDs, they do not appear to limit free testosterone.
Neurological and Central Mechanisms
Sexual desire is not solely a peripheral phenomenon. The brain’s reward circuitry — particularly dopaminergic and noradrenergic pathways — drives the motivational aspects of desire, while serotonin activity tends to inhibit it. Declining estrogen affects neurotransmitter balance, which is why mood disorders common to perimenopause (depression, anxiety) are so closely intertwined with changes in sexual interest. The SMWHS longitudinal data found that depressed mood, fatigue, and sleep difficulty were the most consistent predictors of decreased sexual desire — stronger, in multivariate models, than hormone levels alone.
The Cascade Effect: Physical Symptoms as Secondary Drivers
Hot flashes, night sweats, sleep disruption, and genitourinary symptoms (vaginal dryness, dyspareunia) do not directly cause low libido but create significant barriers to sexual engagement. Dyspareunia — pain during intercourse resulting from genitourinary syndrome of menopause (GSM) — can condition a learned aversion to sexual activity over time, further reducing desire through anticipatory pain response. The Study of Women’s Health Across the Nation (SWAN) — a prospective longitudinal cohort of 3,302 women aged 42–52 at baseline, recruited across seven U.S. sites and representing five racial/ethnic groups (white, Black, Japanese American, Chinese American, and Hispanic) — confirmed that pain during intercourse often increases as women progress through perimenopause (Avis et al., 2009).
Will It Come Back? What the Long-Term Research Shows
This is one of the questions women most want answered. The honest answer is nuanced: for most women without treatment, libido changes are more likely to persist and gradually progress than to resolve on their own — which is precisely why early assessment and proactive care matter.
The most rigorous long-term data come from SWAN. In the 2017 analysis by Avis et al., which tracked 1,390 women across up to 14.5 years using 5,798 repeated sexual function assessments, the steepest decline occurred in the 20 months before and the year following the final menstrual period. After that, the decline continued but slowed meaningfully.
Important limitation: These studies tracked women who were not using hormone therapy, reflecting the untreated natural history.
Women using effective treatment may have meaningfully different trajectories.
Here's the important nuance SWAN also found: when social, psychological, and health factors were controlled for, perimenopause was not independently associated with changes in the importance women placed on sex, their emotional satisfaction with a partner, or their experience of physical pleasure. Only desire and pain showed a transition-specific decline (Avis et al., 2009). The meaning and emotional quality of sex does not have to follow the same trajectory as desire frequency — and for many women it doesn’t. Some postmenopausal women describe a sense of greater ease and freedom in their sexuality once hormonal fluctuation settles and pregnancy concern is gone.
The information provided on the Flourishing Through website and mobile application is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. For additional information view our Medical Disclaimer.
Want more research like this, but not ready to join yet?
Get our free Perimenopause Starter Guide and email updates on content delivered to your inbox.